CSI Market
Sign In | Register

T2 Biosystems Inc (TTOO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TTOO Annual Cash Flow →
Quarterly cash flow trends provide additional context on T2 Biosystems Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-32.61
Depreciation & amortization0.19
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.99
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.02
Share-based Compensation2.02
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Production Related Impairments Or Charges-
Operating Lease Right Of Use Asset Amortization-
Derivative Gain Loss On Derivative Net-
Increase Decrease In Contract With Customer Liability-0.02
Investment Income Amortization Of Premium-
Change In Fair Value Of Derivative Related To Term Loan With Related Party-1.21
Change In Fair Value Of Derivative Warrant Liability-0.17
Issuance Costs Related To Common Stock Warrants-
Operating Lease Right Of Use Asset Amortization Expense1.13
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.61
Increase (Decrease) in Accounts Payable2.68
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.28
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.40
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.70
Discontinued operations0.00
Net Cash flow from Operating Activities-27.18
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale of Available-for-sale Securities, Debt0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Decrease in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-8.97
Proceeds From Issuance Of Redeemable Convertible Preferred Stock Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Stock Options Exercised-
Proceeds From Issuance Initial Public Offering Net Of Offering Costs-
Proceeds From Issuance Of Confidentially Marketed Public Offering-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations16.24
Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises0.01
Proceeds From Issuance Secondary Public Offering Net Of Offering Costs-
Proceeds From Issuance Initial Public Offering Net Of Issuance Costs-
Proceeds From Secondary Offering Net Of Issuance Costs6.29
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities13.57
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-27.18
Total Cash Flow-13.61
4 historic quarters locked

Sign in to unlock the full T2 Biosystems Inc cash flow history.

Sign In Create Free Account

About T2 Biosystems Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20240930)
  • Filed with the SEC: November 14, 2024
  • Source: ttoo-20240930.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-126996

Figures are derived from filed reports and may be restated. Historical data is subject to revision.